VALIDATED STABILITY INDICATING HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHIC METHOD FOR REPAGLINIDE API
Journal: Indian Drugs (Vol.52, No. 9)Publication Date: 2015-09-28
Authors : Thakkar P. P.; Patel N. R.; Kothari C. S.; Patel R.; Mehta P. J.;
Page : 48-54
Keywords : ;
Abstract
A simple, precise and accurate stability-indicating high performance thin layer chromatographic method for estimation of repaglinide in bulk drug and in tablet formulation has been developed and validated. The stationary phase used was HPTLC plates precoated with silica gel 60F254 using the mobile phase of chloroform: methanol: ammonia (4.5:1.0:0.05 V/V/V). Densitometric analysis was performed in absorbance mode at 242 nm. The method showed compact bands of drug at RF value of 0.31 ± 0.02. Linear Regression analysis of calibration data showed good linear relationship with r2= 0.9981 in concentration range of 500 - 3000 ng/band. Drug was subjected to ICH-prescribed stress conditions such as acid, base, peroxide, thermal and photolytic degradation and method was found able to separate the peaks for all degradation products from analyte peak. Validation of the developed method was carried out for its specificity, linearity, range, precision, accuracy and robustness. The method was further applied for repaglinide estimation in pharmaceutical tablet formulation and it was found to be reliable. The method was also used successfully to carry out content uniformity test of repaglinide in tablet dosage form.
Other Latest Articles
- DEVELOPMENT OF STABILITY INDICATING RP-HPLC-PDA METHOD FOR THE SIMULTANEOUS ANALYSIS OF NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE IN BULK AND TABLET DOSAGE FORMS
- IMPROVEMENT OF DISSOLUTION RATE OF FEBUXOSTAT USING HYBRID TECHNIQUE OF SPHERICAL CRYSTALLIZATION AND SOLID DISPERSION
- IMPROVEMENT OF DISSOLUTION RATE OF FEBUXOSTAT USING HYBRID TECHNIQUE OF SPHERICAL CRYSTALLIZATION AND SOLID DISPERSION
- EMERGING TREND IN ADRESSING THE CHALLENGES TO ORAL NANOCURCUMIN DELIVERY TO IMPROVE QUALITY OF LIFE OF PATIENTS SUFFERING FROM CANCER
- FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF RANITIDINE HYDROCHLORIDE
Last modified: 2017-09-07 14:42:01